The identification of HER2 aberrations in metastatic G&CRC and its appropriate treatment selection and management of AEs remains an ongoing challenge in oncology care that requires continued efforts to remain up-to-date regarding the value of testing. Here, ERBB2 is linked to colorectal carcinoma.